ProtAffin has developed the CellJammer® discovery technology to generate biopharmaceutical compounds addressing many high priority disease targets in the pharmaceutical industry. Through this technology ProtAffin has created a pipeline of glycan-binding decoy proteins that cause potent down-regulation of protein function with applications in inflammation, respiratory diseases and oncology. The approach is applicable to over 900 targets contained in a proprietary database, including chemokines and growth factors.